MARKET

GLUE

GLUE

Monte Rosa Therapeutics, Inc.
NASDAQ
17.92
-0.58
-3.14%
After Hours: 17.95 +0.03 +0.17% 17:00 02/13 EST
OPEN
18.78
PREV CLOSE
18.50
HIGH
19.24
LOW
17.79
VOLUME
764.71K
TURNOVER
--
52 WEEK HIGH
25.77
52 WEEK LOW
3.500
MARKET CAP
1.37B
P/E (TTM)
71.54
1D
5D
1M
3M
1Y
5Y
1D
Monte Rosa Therapeutics Files Prospectus For Offering Mixed Shelf; Terms Not Disclosed
Benzinga · 2d ago
Monte Rosa Therapeutics files automatic mixed securities shelf
TipRanks · 2d ago
MONTE ROSA THERAPEUTICS INC FILES FOR MIXED SHELF OFFERING, SIZE NOT DISCLOSED - SEC FILING
Reuters · 2d ago
Monte Rosa Therapeutics Appoints Matthew Bowen as Corporate Controller
Reuters · 3d ago
Weekly Report: what happened at GLUE last week (0202-0206)?
Weekly Report · 4d ago
Weekly Report: what happened at GLUE last week (0126-0130)?
Weekly Report · 02/02 10:36
Weekly Report: what happened at GLUE last week (0119-0123)?
Weekly Report · 01/26 10:35
A Look At Monte Rosa Therapeutics (GLUE) Valuation After Positive MRT-8102 Phase 1 Interim Data
Simply Wall St · 01/21 03:27
More
About GLUE
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Webull offers Monte Rosa Therapeutics Inc stock information, including NASDAQ: GLUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLUE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GLUE stock methods without spending real money on the virtual paper trading platform.